Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal ACYW135 polysaccharide conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal ACYW135 polysaccharide conjugate vaccines are inactivated (non-live) vaccines that protect against invasive disease caused by *Neisseria meningitidis* serogroups A, C, W-135, and Y. These quadrivalent vaccines contain capsular polysaccharides from each of the four serogroups chemically linked (conjugated) to a carrier protein such as diphtheria toxoid or tetanus toxoid. The conjugation enhances immunogenicity by inducing a T-cell dependent immune response and promoting immunological memory. They are indicated for active immunization to prevent invasive meningococcal disease in children and adults. The primary indication is prevention of life-threatening illnesses such as meningitis and septicemia caused by these serogroups. Major brands include Menactra (Sanofi), Menveo (GSK), MenQuadfi (Sanofi), and Nimenrix (Pfizer). These vaccines do not protect against group B *Neisseria meningitidis*.
- Brand names
- MenactraMenveoMenQuadfiNimenrix
- Other names
- meningococcal groups A, C, Y, and W-135 vaccineMenACWY vaccinequadrivalent meningococcal conjugate vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)Neisseria meningitidis capsular polysaccharide
Beyond the preview
Go deeper on meningococcal ACYW135 polysaccharide conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal ACYW135 polysaccharide conjugate vaccine.